Research Analysts Offer Predictions for NMRA Q1 Earnings

Neumora Therapeutics, Inc. (NASDAQ:NMRA) – Research analysts at William Blair raised their Q1 2025 earnings estimates for Neumora Therapeutics in a report released on Monday, March 3rd. William Blair analyst M. Minter now anticipates that the company will post earnings of ($0.37) per share for the quarter, up from their previous forecast of ($0.47). William Blair has a “Outperform” rating on the stock. The consensus estimate for Neumora Therapeutics’ current full-year earnings is ($1.61) per share. William Blair also issued estimates for Neumora Therapeutics’ Q2 2025 earnings at ($0.39) EPS, Q3 2025 earnings at ($0.41) EPS, Q4 2025 earnings at ($0.43) EPS, FY2025 earnings at ($1.60) EPS, FY2026 earnings at ($1.74) EPS, FY2027 earnings at ($1.85) EPS, FY2028 earnings at ($1.48) EPS and FY2029 earnings at ($0.26) EPS.

Neumora Therapeutics (NASDAQ:NMRA) last issued its earnings results on Thursday, March 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.09.

A number of other equities research analysts have also weighed in on NMRA. Royal Bank of Canada reiterated a “sector perform” rating and set a $4.00 price objective on shares of Neumora Therapeutics in a report on Tuesday. HC Wainwright reduced their price objective on shares of Neumora Therapeutics from $30.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday. Needham & Company LLC reissued a “buy” rating and set a $5.00 target price on shares of Neumora Therapeutics in a research report on Tuesday. Finally, Bank of America dropped their price objective on shares of Neumora Therapeutics from $22.00 to $7.00 and set a “buy” rating on the stock in a report on Monday, January 6th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $11.50.

Neumora Therapeutics Stock Up 1.4 %

Shares of NASDAQ:NMRA opened at $1.43 on Thursday. Neumora Therapeutics has a 52 week low of $1.35 and a 52 week high of $21.00. The firm has a fifty day simple moving average of $2.83 and a two-hundred day simple moving average of $8.76. The stock has a market capitalization of $231.03 million, a P/E ratio of -0.76 and a beta of 2.59.

Hedge Funds Weigh In On Neumora Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. acquired a new position in Neumora Therapeutics in the 4th quarter valued at about $61,000. PNC Financial Services Group Inc. purchased a new position in Neumora Therapeutics in the 4th quarter worth approximately $64,000. Quantbot Technologies LP purchased a new position in Neumora Therapeutics in the 4th quarter worth approximately $92,000. PEAK6 LLC acquired a new position in shares of Neumora Therapeutics in the 4th quarter valued at approximately $117,000. Finally, EntryPoint Capital LLC acquired a new position in shares of Neumora Therapeutics in the 4th quarter valued at approximately $135,000. 47.65% of the stock is currently owned by hedge funds and other institutional investors.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.